Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
"Federal debt, which is already high by historical standards, is on an unsustainable course," CBO director Phillip Swagel said in the report.Politicsread more
Target CEO Brian Cornell still thinks the U.S. consumer is strong and spending. Target's latest quarterly results showed the big-box retailer is benefiting from that.Retailread more
"If you look at the market over the past week, stocks don't need any help. They are roaring ahead, without the Fed doing anything," says the longtime market strategist.Marketsread more
Stocks rose on Wednesday as strong quarterly results from retailers such as Target and Lowe's lifted investor sentiment.US Marketsread more
President Trump insists the economy is healthy and says the only thing holding U.S. growth back is the Federal Reserve.Marketsread more
Trading volumes this week are well below their recent averages and that means this comeback may be suspect.Marketsread more
The rule could defy a 2015 Flores Settlement Agreement court order that says families cannot be held in detention for more than 20 days.Politicsread more
A key indicator for the commercial real estate market is showing signs of weakness, and uncertainty in the economy over the trade war and interest rates may be to blame.Real Estateread more
Bank of America CEO Brian Moynihan is not worried about an economic slowdown, saying the U.S. consumer is still in a strong place.Banksread more
In a second-round of tweets aimed at the U.S. central bank, the president asked, "WHERE IS THE FEDERAL RESERVE?"Marketsread more
May 8 (Reuters) - U.S. Centers for Medicare & Medicaid Services on Wednesday said it will require drugmakers to disclose the list price for their prescription drugs in direct-to-consumer television advertisements, part of the Trump administration's efforts to lower costs for U.S. consumers.
The list price should be included if it is equal to or greater than $35 for a month's supply or the usual course of therapy. CMS said that the 10 most commonly advertised drugs have list prices ranging from $488 to $16,938 per month or usual course of therapy.
"Patients have the right to know the prices of healthcare services, and CMS is serious about empowering patients with this information across-the-board," CMS Administrator Seema Verma said in a statement.
The rule, which was finalized on Tuesday, was originally suggested as part of President Donald Trump's "blueprint" to lower U.S. drug prices last May.
Drug companies have argued against the proposed rule, saying list prices do not reflect the final amount paid by patients as it excludes rebates and discounts drugmakers may offer.
The Pharmaceutical Research and Manufacturers of America (PhRMA), the industry's top U.S. lobbying group, said in October that including the list price in commercials could discourage patients from seeking needed medical care. (Reporting by Ankur Banerjee in Bengaluru and Michael Erman in New York; Editing by Sriraj Kalluvila and Andrea Ricci)